This a study of V116 in adults ≥50 years of age who concomitantly received Influenza vaccine. The primary objectives of this study are to evaluate the safety, tolerability, and immunogenicity of V116 when administered concomitantly with Quadrivalent Influenza Vaccine (QIV) compared with V116 administered sequentially with QIV. The primary hypotheses state that immune responses to V116 and to QIV are non-inferior when administered concomitantly as compared with sequential administration as measured by serotype-specific opsonophagocytic activity (OPA) for V116 and hemagglutination inhibition (HAI) geometric mean titers (GMTs) for QIV, at 30 days postvaccination.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants With Solicited Injection-site Adverse Events (AEs)
Timeframe: Up to 5 days post-vaccination
Number of Participants With Solicited Systemic AEs
Timeframe: Up to 5 days post-vaccination
Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs)
Timeframe: Up to ~6 months postvaccination with V116
Geometric Mean Titer (GMT) of Serotype-specific Opsonophagocytic Activity (OPA) Responses
Timeframe: 30 days after V116 vaccination (Day 30 for concomitant group and Day 59 for sequential group)
GMT of Influenza Strain-specific Hemagglutination Inhibition (HAI)
Timeframe: Day 30